Zacks Equity Research Analyst Blog

Visit Zacks Equity Research Analyst Blog

ViroPharma Value Worth Buying

Posted on June 24, 2008

ViroPharma could be a dramatically different-looking company in 2010 if pipeline antiviral candidate Camvia succeeds in treating cytomegalovirus disease....

Original article link


disease , pipeline